Announcements Trials

Browse Landscape

Phase

Status

Terminated 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 392 Lymphoid 208 Other hematologic neoplasm 153 Genitourinary 24 Gastrointestinal 21 Thoracic 16 Gynecologic 14 Breast 14 Tumor-Agnostic 11 Myeloid 11 Head & Neck 10 CNS 10 Sarcoma 9 Dermatologic 9 Classical hematology 5 Other solid neoplasm 4 Other neoplasm 1 Other 1 Endocrine 1

Conditions

Pituitary Neoplasms 1 Pituitary Diseases 1

Interventions

Everolimus 32 Octreotide 15 Cisplatin 14 pasireotide 13 Sunitinib 13 Temozolomide 11 pembrolizumab 10 Etoposide 10 Doxorubicin 10 lanreotide 9 Magnetic Resonance Spectroscopy 9 Bevacizumab 9 lutetium Lu 177 dotatate 8 gallium Ga 68 dotatate 8 Sorafenib 8 Paclitaxel 8 3-Iodobenzylguanidine 8 lenvatinib 7 pazopanib 6 Radiotherapy 6 Positron Emission Tomography Computed Tomography 6 surufatinib 5 cabozantinib 5 avelumab 5 Thyrotropin Alfa 5 Surgical Procedures, Operative 5 Radiosurgery 5 Nivolumab 5 Mitotane 5 Irinotecan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Dexamethasone × Endocrine × Clear all

NCT02084134 2018-04-11

Steroid

Washington University School of Medicine

Phase NA Completed

43 enrolled 8 charts

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡